KR100444102B1 - Cosmetic composition for trichogenousness containing Thujae semen extract - Google Patents
Cosmetic composition for trichogenousness containing Thujae semen extract Download PDFInfo
- Publication number
- KR100444102B1 KR100444102B1 KR10-2001-0082716A KR20010082716A KR100444102B1 KR 100444102 B1 KR100444102 B1 KR 100444102B1 KR 20010082716 A KR20010082716 A KR 20010082716A KR 100444102 B1 KR100444102 B1 KR 100444102B1
- Authority
- KR
- South Korea
- Prior art keywords
- white porcelain
- extract
- present
- hair
- hair growth
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 239000002537 cosmetic Substances 0.000 title abstract description 18
- 210000000582 semen Anatomy 0.000 title description 2
- 229910052573 porcelain Inorganic materials 0.000 claims abstract description 73
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims 1
- 230000003779 hair growth Effects 0.000 abstract description 33
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 24
- 230000001737 promoting effect Effects 0.000 abstract description 21
- 230000002401 inhibitory effect Effects 0.000 abstract description 19
- 201000004384 Alopecia Diseases 0.000 abstract description 15
- 230000003676 hair loss Effects 0.000 abstract description 13
- 208000024963 hair loss Diseases 0.000 abstract description 13
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 abstract description 12
- 229960003473 androstanolone Drugs 0.000 abstract description 12
- 239000003960 organic solvent Substances 0.000 abstract description 12
- 229940088597 hormone Drugs 0.000 abstract description 10
- 239000005556 hormone Substances 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 230000003658 preventing hair loss Effects 0.000 abstract description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- 229960003604 testosterone Drugs 0.000 description 16
- 238000012360 testing method Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 239000003990 capacitor Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 210000004209 hair Anatomy 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 229940093499 ethyl acetate Drugs 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000002374 sebum Anatomy 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002985 plastic film Substances 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960004039 finasteride Drugs 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003659 hair regrowth Effects 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- MUMGGOZAMZWBJJ-JQSYSRDDSA-N (8r,9s,10r,13s,14s,17s)-17-hydroxy-10,13-dimethyl-1,2,6,7-tetratritio-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2C([3H])C([3H])C3=CC(=O)C([3H])C([3H])[C@]3(C)[C@H]21 MUMGGOZAMZWBJJ-JQSYSRDDSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- OKJCFMUGMSVJBG-ABEVXSGRSA-N Delta(1)-dihydrotestosterone Chemical compound C1C(=O)C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OKJCFMUGMSVJBG-ABEVXSGRSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000002924 Platycladus orientalis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- HTRXGEPDTFSKLI-UHFFFAOYSA-N butanoic acid;ethyl acetate Chemical compound CCCC(O)=O.CCOC(C)=O HTRXGEPDTFSKLI-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- YRUMDWGUXBZEPE-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1.C1CCCCC1 YRUMDWGUXBZEPE-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- JQOAQUXIUNVRQW-UHFFFAOYSA-N hexane Chemical compound CCCCCC.CCCCCC JQOAQUXIUNVRQW-UHFFFAOYSA-N 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000011272 imaginal disc-derived genitalia development Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940072254 proscar Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000004378 sebocyte Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- OWGHQYPQNSZTFQ-UHFFFAOYSA-M triethyl(octadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](CC)(CC)CC OWGHQYPQNSZTFQ-UHFFFAOYSA-M 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9761—Cupressaceae [Cypress family], e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 백자인 추출물을 함유하는 발모촉진용 화장료 조성물에 관한 것이다. 더욱 상세하게는, 본 발명은 발모효과가 있는 것으로 알려진 백자인의 유기용매 추출물이 탈모를 유발하는 활성 남성호르몬인 디하이드로테스토스테론의 생성을 촉진하는 5알파-환원효소를 저해하는 효과가 있음을 밝히고, 이러한 백자인 추출물을 유효성분으로 함유함으로써 탈모를 예방하고 발모를 촉진하는 효과가 있는 화장료 조성물에 관한 것이다.The present invention relates to a hair growth promoting cosmetic composition containing white porcelain extract. More specifically, the present invention reveals that the organic solvent extract of white porcelain known to have a hair growth effect has an effect of inhibiting 5 alpha-reductase which promotes the production of dihydrotestosterone, an active male hormone causing hair loss, The present invention relates to a cosmetic composition having the effect of preventing hair loss and promoting hair growth by containing such white porcelain extract as an active ingredient.
Description
본 발명은 백자인 추출물을 함유하는 발모촉진용 화장료 조성물에 관한 것이다. 더욱 상세하게는, 본 발명은 발모효과가 있는 것으로 알려진 백자인의 유기용매 추출물이 탈모를 유발하는 활성 남성호르몬인 디하이드로테스토스테론의 생성을촉진하는 5알파-환원효소를 저해하는 효과가 있음을 밝히고, 이러한 백자인 추출물을 유효성분으로 함유함으로써 탈모를 예방하고 발모를 촉진하는 효과가 있는 화장료 조성물에 관한 것이다.The present invention relates to a hair growth promoting cosmetic composition containing white porcelain extract. More specifically, the present invention reveals that the organic solvent extract of white porcelain known to have a hair growth effect has an effect of inhibiting 5 alpha-reductase which promotes the production of dihydrotestosterone, an active male hormone which causes hair loss, The present invention relates to a cosmetic composition having the effect of preventing hair loss and promoting hair growth by containing such white porcelain extract as an active ingredient.
남성의 형질발현에 있어서, 남성 성충동, 골격근 증가, 남성외부생식기 발달, 음낭성장, 정자형성 등은 테스토스테론이 관여하고 여드름, 피지증가, 탈모 및 전립선비대증 등은 디하이드로테스토스테론이 해당 조직에서 관여하는 것으로 알려져 있다(J. Invest. Dermatol. 1995; 105(2): 209-14). 남성 호르몬 의존성 질환 중 남성형 탈모는 미용을 중시하는 현대사회의 남성들에게 심각한 정신적 고통을 주고 있기 때문에, 탈모의 기전을 밝히고 이를 개선하기 위한 연구가 활발히 진행되고 있다.In male expression, testosterone is involved in male impulse, skeletal muscle increase, male external genital development, scrotum growth, and spermatogenesis, and dehydrotestosterone is involved in acne, sebum increase, hair loss and prostatic hyperplasia. Known ( J. Invest. Dermatol . 1995; 105 (2): 209-14). Since male-type hair loss among male hormone-dependent diseases causes serious mental pain for men in the modern society, which emphasizes beauty, researches are being actively conducted to clarify and improve the mechanism of hair loss.
5알파-환원효소(5α-reductase)는 피지선, 모낭, 전립선 또는 부고환 등 남성호르몬 반응성 조직에 존재하며 정소에서 생합성되는 남성호르몬인 테스토스테론(testosterone)을 활성 남성 호르몬인 디하이드로테스토스테론 (dihydrotestosterone, DHT)으로 전환시키는 데 관여하는 환원효소인데, 이 전환과정에는 NADPH가 조효소로서 이용되는 것으로 알려져 있다. 사춘기 이후 과량 분비된 디하이드로테스토스테론은 피지세포(sebocyte)에서 피지를 과잉 생성하는 주 원인 물질로 작용하여 여드름 및 남성형 탈모를 유발한다. 특히, 여러 모낭 세포에서도 테스토스테론에 비하여 디하이드로테스토스테론이 호르몬 수용체에 더욱 잘 결합하기 때문에 탈모를 일으키는 원인을 제공한다. 이에, 디하이드로테스토스테론의 생성을 촉진하는 5알파-환원효소의 활성 및 생성을 억제하는 물질을 개발하여 발모제 또는 탈모방지제로 이용하기 위한 연구들이 활발이 진행되고 있다.5alpha-reductase is present in male hormone-reactive tissues such as sebaceous glands, hair follicles, prostate or epididymis, and is a testosterone, a male hormone that is biosynthesized in the testes. It is known to be a reductase involved in the conversion of NADPH as a coenzyme. Excessive secretion of dihydrotestosterone after puberty acts as a major causative agent in the production of sebum in sebocytes, causing acne and male hair loss. In particular, many hair follicle cells provide a cause for hair loss because dihydrotestosterone binds to hormone receptors better than testosterone. Accordingly, studies are being actively conducted to develop a substance that inhibits the activity and production of 5-alpha-reductase, which promotes the production of dihydrotestosterone, and to use it as a hair regrowth or hair loss prevention agent.
남성형 탈모의 치료를 위해 종래에는 에스트로겐 등의 여성 호르몬을 이용해왔으나, 여성 호르몬제 등은 그 효과에 비하여 피부 염증 발생, 호르몬 투여에 따른 부작용 발생 등의 보고가 있어 현재는 사용을 중단하거나 아주 극미량을 사용하고 있는 실정이다. 최근, 미국의 머크사에서 5알파-환원효소의 작용을 저해하여 디하이드로테스토스테론의 생성을 억제하는 약제인 피나스테라이드(finasteride, proscar)를 합성하여 이를 경구투여용 발모제로 시판하고 있으나, 고가이고 두피 도포용으로 제조하여 직접 도포하는 경우 효과가 떨어지며 경구투여에 따른 기타 부작용이 발생하는 등 사용에 제한이 있는 실정이다.Conventionally, female hormones such as estrogen have been used for the treatment of androgenetic alopecia, but female hormones have been reported to cause skin inflammation and side effects due to hormone administration. I'm using it. Recently, Merck in the United States has synthesized finasteride (finasteride, proscar), a drug that inhibits the action of 5 alpha-reductase and inhibits the production of dihydrotestosterone, and is commercially available as an oral administration hair regrowth, but is expensive and applied to the scalp If manufactured for direct application and the effect is ineffective and other side effects of oral administration occurs, there is a limit to use.
이에, 본 발명자들은 예로부터 탈모예방 및 발모촉진효과가 있는 것으로 알려진 백자인을 유기용매로 추출하여 백자인 추출물을 제조하고 그 생리학적 기전을 연구한 결과, 본 발명 백자인 추출물이 테스토스테론을 디하이드로테스토스테론으로 전환시켜 탈모를 유발하는 5알파-환원효소를 효과적으로 저해하는 유효물질을 다량 함유하고 있어 뛰어난 발모촉진효과가 있음을 발견하고 이러한 백자인 추출물을 함유하는 발모촉진용 화장료 조성물을 제조함으로써 본 발명을 완성하였다.Accordingly, the present inventors have extracted white porcelain, known to have hair loss prevention and hair growth promoting effects, using organic solvents, and have studied the physiological mechanism of white porcelain. As a result, the white porcelain extract of the present invention converts testosterone to dihydrotestosterone. The present invention was completed by finding a hair growth promoting cosmetic composition containing such white porcelain extract because it contains a large amount of an effective substance that effectively inhibits 5 alpha-reductase which causes hair loss.
따라서, 본 발명의 목적은 유기용매를 이용하여 백자인 유효성분을 추출하는데 데 있다. 또한, 상기 백자인 추출물의 유효성분이 5알파-환원효소 억제효과가 있음을 밝히고, 이를 유효성분으로 함유함으로써 탈모를 예방하고 발모 또는 육모를 촉진하는 발모촉진용 화장료 조성물을 제공하는 데 있다.Therefore, an object of the present invention is to extract the active ingredient white porcelain using an organic solvent. In addition, the active ingredient of the white porcelain extract has been found to have a 5 alpha-reductase inhibitory effect, by containing it as an active ingredient to provide a cosmetic composition for promoting hair growth to prevent hair loss and promote hair growth or hair growth.
도 1은 남성 호르몬의 모발세포에서의 효과 및 전달 과정을 도시한 것이다.Figure 1 shows the effect and delivery process of the male hormone in the hair cells.
도 2는 발모촉진 유효성분을 함유하는 본 발명 백자인 추출물을 분리하는 과정을 도시한 것이다.Figure 2 shows the process of separating the white porcelain extract of the present invention containing the hair growth promoting active ingredient.
도 3은 발모촉진 유효성분을 함유하는 본 발명 백자인 추출물 제조예의 각 용매추출물별 5알파-환원효소 저해 효과를 도시한 것이다.Figure 3 shows the effect of inhibiting 5 alpha-reductase for each solvent extract of the white porcelain extract preparation of the present invention containing the hair growth promoting active ingredient.
도 4는 발모촉진 유효성분을 함유하는 본 발명 백자인 추출물의 농도별 5알파-환원효소 저해 효과를 도시한 것이다.Figure 4 shows the effect of inhibiting 5 alpha-reductase by concentration of the white porcelain extract of the present invention containing the hair growth promoting active ingredient.
도 5는 발모촉진 유효성분을 함유하는 본 발명 백자인 추출물의 퍼지랫트(Fuzzy rat)를 이용한 5 알파-환원효소 저해 효과 시험 결과이다.5 is a test result of 5 alpha-reductase inhibitory effect using the fuzzy rat of the white porcelain extract of the present invention containing the hair growth promoting active ingredient.
상기한 목적을 달성하기 위하여, 본 발명은 천연 백자인 생약에 유기용매를 혼합하여 가열추출한 후 감압농축함으로써, 특히 5알파-환원효소를 저해하는 효과가 있는 백자인 추출물을 획득하고, 이러한 백자인 추출물을 유효성분으로 함유함으로써 탈모예방 및 발모촉진효과가 있는 발모촉진용 화장료 조성물을 제조함에 그 특징이 있다.In order to achieve the above object, the present invention is to extract the white porcelain extract having the effect of inhibiting the 5 alpha-reductase by heating and extracting the natural solvent and the organic solvent mixed with the organic solvent and heat-extracted, and the white porcelain extract is effective It is characterized by producing a cosmetic composition for promoting hair growth that is effective in preventing hair loss and promoting hair growth by containing it as a component.
본 발명 백자인 추출물 함유 발모촉진용 화장료 조성물은 탈모를 유도하는 디하이드로테스토스테론의 생성 및 활성을 촉진하는 5알파-환원효소의 작용을 억제하는 뛰어난 효과가 있다.The white porcelain extract-containing hair growth promoting cosmetic composition of the present invention has an excellent effect of inhibiting the action of 5-alpha-reductase, which promotes the production and activity of dihydrotestosterone that induces hair loss.
즉, 본 발명의 백자인 추출물은 5알파-환원효소에 특이적인 효과를 나타냄으로써 치료상 또는 미용상 목적을 위한 선택적 처방에 유리하다. 따라서, 본 발명은 5알파-환원효소 저해효과가 있는 백자인 추출물을 제조하고 이를 함유한 발모촉진용 화장료 조성물을 제조하여 탈모예방 및 발모촉진용으로 사용하는 것이 목적이나, 과다한 피지의 분비로 인한 여드름, 지루성 피부염 또는 비듬 등의 치료용 제제 또는 화장료 조성물로도 제조하여 이용할 수 있다. 또한, 5알파-환원효소 저해효과가 있는 것으로 밝혀진 본 발명 백자인 추출물을 남성형 탈모증 이외에도 전립선 암, 전립선 비대증 등 5알파-환원효소가 관여되는 각종 질환의 치료 및 예방을 위한 제제에 첨가하여 이용할 수 있다.That is, the white porcelain extract of the present invention exhibits a specific effect on 5-alpha-reductase, which is advantageous for selective prescription for therapeutic or cosmetic purposes. Therefore, the present invention is to prepare a white porcelain extract having a 5 alpha-reductase inhibitory effect and to prepare a cosmetic composition for promoting hair growth using the same to prevent hair loss and promote hair growth, but acne due to excessive sebum secretion It can also be manufactured and used as a therapeutic agent or cosmetic composition, such as seborrheic dermatitis or dandruff. In addition, the white porcelain extract of the present invention, which has been found to have an effect of inhibiting 5 alpha-reductase, may be used in addition to male alopecia in preparations for the treatment and prevention of various diseases involving 5 alpha-reductase, such as prostate cancer and prostatic hyperplasia. .
이하, 본 발명의 구성을 상세히 설명한다.Hereinafter, the configuration of the present invention will be described in detail.
5알파-환원효소 저해효과가 있어 탈모방지 및 발모촉진 효과가 있는 본 발명백자인 추출물은;The present invention white phosphorus extract has a 5 alpha-reductase inhibitory effect to prevent hair loss and promote hair growth;
(1) 백자인에 유기용매를 백자인 생약 건조중량에 대하여 단독으로 2∼5배의 용량으로 첨가 혼합하여 백자인 추출물을 제조하는 단계;(1) preparing a white porcelain extract by adding and mixing an organic solvent with white porcelain in a dose of 2 to 5 times alone with respect to dry weight of the crude white porcelain;
` (2) 냉각콘덴서가 장착된 추출기에서 상기 백자인-유기용매 혼합물을 가열하여 백자인 추출액을 제조하는 단계;`(2) preparing a white porcelain extract by heating the white porcelain-organic solvent mixture in an extractor equipped with a cooling capacitor;
(3) 상기 백자인 추출액을 냉각콘덴서가 달린 감압 증발기에서 감압농축하고 완전히 건조시키는 단계;(3) concentrating the white porcelain extract under reduced pressure in a reduced pressure evaporator equipped with a cooling capacitor and completely drying it;
를 포함하여 구성되느 방법에 의하여 제조됨을 특징으로 한다.It is characterized by being manufactured by a method comprising a.
상기 백자인은 생약제로 판매되고 있는 것을 이용할 수 있다.The white porcelain can be used that is sold as a herbal medicine.
상기 유기용매로는 탄소수 1∼4개의 무수 또는 함수 저급 알코올(alcohol), 헥산(hexane), 에틸에테르(ethylether) 또는 에틸아세테이트(ethylacetate) 등을 이용할 수 있다. 이 때, 상기 유기용매 중 한가지 용매만을 사용하여 단순 추출할 수 있으며, 상기 유기용매와 물을 사용하여 단계적으로 분획추출할 수도 있다.As the organic solvent, anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms, hexane, hexane, ethyl ether or ethylacetate may be used. At this time, it can be simply extracted using only one solvent of the organic solvent, it may be fractionally extracted using the organic solvent and water.
상기 (2)의 가열시 50∼100℃로 1∼10시간 동안 가열하는 것이 바람직하나, 이에 한정되는 것은 아니다. 또한, 상기와 같은 가열 추출 방법 이외에도 백자인을 상기 유기용매에 0∼40℃에서 1∼30일간 침적하는 방법으로도 백자인 유효성분을 추출할 수 있다.In the heating of (2), it is preferable to heat at 50 to 100 ° C. for 1 to 10 hours, but is not limited thereto. In addition to the heat extraction method described above, an active ingredient of white porcelain may be extracted by depositing white porcelain in the organic solvent at 0 to 40 ° C. for 1 to 30 days.
본 발명에서 이용한 백자인(柏子仁,Thujae semenLinne)은 길이 3~5㎜, 지름 2~3㎜로 그 모양은 난원형~긴 타원형이거나 또는 긴 원주형인 측백나무(Thuja orientalis)의 종자이다. 바깥 면은 엷은 황백색 또는 담황갈색이고, 오래되면 점차 변하여 황갈색이 되며, 기름이 스며 나온다. 종자의 바깥 면은 흔히 얇은 막질의 내종피로 싸여있고, 끝은 대개 뾰족하며, 원삼능형으로 진한 갈색의 점이 있다. 아래쪽은 둔한 원형으로 색이 엷다. 횡단면을 현미경으로 살펴보면 백색 또는 황백색이고 배유가 많으며 풍부한 지방질이 함유되어 있다(대한약전외 한약 규격집). 달고 평하며 독이 없고 향기로우며, 심장에 작용하여 혈액을 보충하고 정신을 안정시켜 땀을 멎게 하는 작용을 한다. 간장과 신장을 윤택하게 하고, 허리 또는 뼈마디가 무겁고 아픈 증상을 치료하며, 양심안신(養心安神), 윤장통편(潤腸通便)의 효능이 있는 것으로 알려져 있다(동양학 개론;서경출판사).White porcelain (柏子仁, Thujae semen Linne) used in the present invention is 3 to 5 mm in length, 2 to 3 mm in diameter, the shape is a seed of the Thuja orientalis oval-long oval or long columnar. The outer surface is light yellowish white or light yellowish brown, and when it is old, it gradually changes to yellowish brown color, and oil leaks out. The outer surface of the seed is often enclosed by a thin membranous inner epithelium, the tip is usually pointed, and the round triad has dark brown spots. The lower part is a dull round and light in color. When viewed under a microscope, it is white or yellowish white, rich in endosperm, and rich in fat. It is sweet, flat, nontoxic and fragrant, and works on the heart to replenish blood and to stabilize the mind to stop sweating. It is known to soothe the liver and kidneys, to treat heavy and painful symptoms of the lower back or bone, and to have the effect of conscience and deity (, 心 安神), Yunjangtongpyeon (개 通便). .
상기의 방법으로 제조한 발모촉진효과가 있는 백자인 추출물은 마우스의 전립선에서 추출한 5알파-환원효소를 이용한 시험 및 디하이드로테스토스테론의 작용으로 피지가 과다 발생되어 피부색이 누렇게 변하는 퍼지렛드를 이용한 시험을 통하여 탁월한 5알파-환원효소 억제효과가 있는 것으로 나타났다. 또한, 마우스를 이용한 모발 생장 효과 시험에서도 유의적인 모발 생장 촉진효과가 있는 것으로 나타났다.White porcelain extract with hair growth promoting effect prepared by the above method was tested using 5-alpha-reductase extracted from the prostate gland of the mouse and the test using fuzzy red which caused excessive sebum due to the action of dihydrotestosterone and yellowed skin color. It was shown to have an excellent 5-alpha-reductase inhibitory effect. In addition, the hair growth effect test using a mouse showed a significant hair growth promoting effect.
이 때, 첨가하는 백자인 추출물의 양은 화장료 조성물의 건조 중량에 대하여 0.0001∼5중량%(w/w), 바람직하게는 0.001∼1중량%(w/w)의 양으로 배합할 수 있다. 본 발명의 발모촉진용 화장료 조성물은 두발 또는 피부에 적용할 수 있는 유연화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 팩, 헤어토닉, 헤어로션, 샴푸 및 토닉등의 제형으로 제조하여 사용할 수 있다.At this time, the amount of white porcelain extract to be added may be blended in an amount of 0.0001 to 5% by weight (w / w), preferably 0.001 to 1% by weight (w / w) based on the dry weight of the cosmetic composition. The cosmetic composition for promoting hair growth of the present invention can be prepared and used in formulations such as flexible cosmetics, nourishing cosmetics, nourishing cream, massage cream, essence, pack, hair tonic, hair lotion, shampoo and tonic that can be applied to hair or skin. have.
이하, 본 발명의 구성을 제조예 및 시험예를 들어 상세히 설명하고자 하지만 본 발명의 권리범위가 이들에만 한정되는 것은 아니다.Hereinafter, the configuration of the present invention will be described in detail by the production examples and test examples, but the scope of the present invention is not limited thereto.
제조예 1. 백자인 추출물 Ⅰ의 제조Preparation Example 1 Preparation of White Porcelain Extract I
백자인 100g에 70% 에탄올(ethanol)을 250㎖ 가하고 냉각콘덴서가 달려있는 추출기에서 약 2시간동안 끓여서 추출한 후 여과하여 찌꺼기를 제거하고 백자인 추출액을 제조하였다. 상기 제조한 백자인 추출액을 냉각콘덴서가 달린 증류장치를 이용하여 60oC에서 감압 농축하여 건조된 백자인 추출물 Ⅰ을 8g 획득하였다.250 g of 70% ethanol (ethanol) was added to 100 g of white porcelain, boiled for about 2 hours in an extractor equipped with a cooling capacitor, extracted, filtered to remove the residue, and white porcelain extract was prepared. The white porcelain extract obtained above was concentrated under reduced pressure at 60 ° C. using a distillation apparatus equipped with a cooling capacitor to obtain 8 g of dried white porcelain extract I.
제조예 2. 백자인 추출물 Ⅱ의 제조Preparation Example 2 Preparation of White Porcelain Extract II
백자인 100g에 헥산(hexane)을 250㎖ 가하고 냉각콘덴서가 달려있는 추출기에서 약 2시간동안 끓여서 추출한 후 여과하여 찌꺼기를 제거하고 백자인 추출액을 제조하였다. 상기 제조한 백자인 추출액을 냉각콘덴서가 달린 증류장치를 이용하여 60oC에서 감압 농축하여 건조된 백자인 추출물 Ⅱ을 6g 획득하였다.250 mL of hexane (hexane) was added to 100 g of white porcelain, boiled and extracted for about 2 hours in an extractor equipped with a cooling capacitor, filtered to remove residue, and white porcelain extract was prepared. The white porcelain extract obtained above was concentrated under reduced pressure at 60 ° C. using a distillation apparatus equipped with a cooling capacitor to obtain 6 g of dried porcelain extract II.
제조예 3. 백자인 추출물 Ⅲ의 제조Preparation Example 3 Preparation of White Porcelain Extract III
백자인 100g에 에틸아세테이트(ethylacetate)를 200㎖ 가하고 냉각콘덴가 달려있는 추출기에서 약 2시간동안 끓여서 추출한 후 여과하여 찌꺼기를 제거하고 백자인 추출액을 제조하였다. 상기 제조한 백자인 추출액을 냉각콘덴서가 달린 증류장치를 이용하여 50oC에서 감압 농축하여 건조된 백자인 추출물 Ⅲ을 4g 획득하였다.200 ml of ethyl acetate (ethylacetate) was added to 100 g of white porcelain, boiled and extracted for about 2 hours in an extractor with cooling condensate, filtered to remove residue, and white porcelain extract was prepared. The white porcelain extract obtained above was concentrated under reduced pressure at 50 ° C. using a distillation apparatus equipped with a cooling capacitor to obtain 4 g of dried white porcelain extract III.
제조예 4. 백자인 추출물 Ⅳ의 제조Preparation Example 4 Preparation of Porcelain Extract IV
백자인 100g에 함수 혹은 무수 에탄올(ethylacohol)을 200㎖ 가하고, 냉각콘덴서가 달려있는 추출기에서 약 2시간동안 끓여서 추출한 후 헥산(hexane)과 물을 각각 200㎖씩 첨가하여 헥산층을 분리하고 위의 추출과정을 반복한다. 여기에 다시 에틸에테르(ethylether)로 용출시킨 후 에틸아세테이트(ethylacetate)와 물을 각각 각각 200㎖씩 첨가하여 에틸아세테이트(ethylacetate)층을 분리하고 냉각콘덴서가 달린 증류장치를 이용하여 50oC에서 감압 농축하여 건조된 백자인 추출물 Ⅳ을 5g 획득하였다.To 100 g of white porcelain, 200 ml of hydrated or anhydrous ethanol (ethylacohol) was added, boiled and extracted for about 2 hours in an extractor equipped with a cooling capacitor, followed by adding 200 ml of hexane and water each to separate the hexane layer, Repeat the process. After eluting with ethyl ether again, ethylacetate and water were added 200ml, respectively, to separate the ethylacetate layer and reduced pressure at 50 o C using a distillation apparatus equipped with a cooling capacitor. Concentrated 5g of dried white porcelain extract IV was obtained.
제형예 1. 백자인 추출물을 함유한 탈모 방지 영양 화장수의 제형예Formulation Example 1 Formulation Example of Anti-Hair Loss Nourishing Lotion Containing White Porcine
제형예 2. 백자인 추출물을 함유한 탈모 방지 헤어 토닉의 제형예Formulation Example 2 Formulation Example of Hair Loss Prevention Hair Tonic Containing White Porcelain Extract
제형예 3. 백자인 추출물을 함유한 탈모 방지 헤어 로션의 제형예Formulation Example 3 Formulation Example of Hair Loss Prevention Hair Lotion Containing White Porcelain Extract
제형예 4. 백자인 추출물을 함유한 탈모 방지 헤어 비누의 제형예Formulation Example 4 Formulation Example of Hair Loss Prevention Hair Soap Containing White Porcelain Extract
상기 제조예 1∼4에서 제조한 본 발명 백자인 추출물Ⅰ∼Ⅳ의 5 알파-환원효소 저해 효과를 알아 보기 위하여 다음의 방법에 따라 시험예를 실시하였다.In order to determine the 5 alpha-reductase inhibitory effect of the extracts I to IV of the present invention white porcelain prepared in Preparation Examples 1 to 4 was carried out according to the test method according to the following method.
시험예 1. 스프라그 다우리 전립선을 이용한 5알파-환원효소 저해 효과 시험Experimental Example 1 Test of 5-alpha-Reductase Inhibitory Effect Using Sprague Dawley Prostate
생후 7∼8주의 성숙한 수컷 스프라그-다우리(Sprague-Dawley)를 디에틸에테르(diethylether)로 치사시킨 후 복부 전립선을 떼내어 결합조직을 제거하였다. 여기에 완충액[0.32M 수크로스(sucrose), 0.1mM 디티오트레이톨(dithiothreitol), 20mM 아세트산나트륨염(sodium acetate)]을 첨가하고 분쇄기로 잘게 자른 후 현탁하였다. 상기 현탁액을 거즈로 여과한 여과액을 1500 ×g에서 원심분리한 후 펠렛(pellet)을 취해 상기 완충액을 혼합하여 20~30㎎/㎖ 농도로 현탁하였다.7-8 weeks old male Sprague-Dawley was killed with diethylether and the abdominal prostate was removed to remove connective tissue. Buffer (0.32M sucrose, 0.1 mM dithiothreitol, 20 mM sodium acetate) was added thereto, chopped finely by a grinder and suspended. The suspension was filtered with gauze, and the filtrate was centrifuged at 1500 x g, and then pellets were taken and the buffer was mixed and suspended at a concentration of 20-30 mg / ml.
상기 현탁액의 일부를 취하여 0.02M 인산 완충액에 넣은 후, 동위 원소인3H 가 붙어있는 기질 테스토스테론과 함께 반응시켜 생성물인 디하이드로테스토스테론의 생성량을 측정하였다. 이 때, 반응 용액은 1mM의 디티오트레이톨, 20mM의 인산염 완충액(pH 6.5), 50μM의 NADPH, [1,2,6,7-3H] 테스토스테론 0.1μCi/테스토스테론(1×10-7M)과 36㎍ 효소 현탁액을 첨가하여 전체 반응액을 565㎕가 되도록 조제하였다.After taking a portion of the suspension was placed in a 0.02M phosphate buffer, it is reacted with a substrate which is a testosterone isotopes 3 H attached to measure the amount of dihydrotestosterone product. At this time, the reaction solution is dithiothreitol, 20mM of phosphate buffer (pH 6.5) in 1mM, of 50μM NADPH, [1,2,6,7- 3 H] testosterone 0.1μCi / testosterone (1 × 10 -7 M ) And 36 μg enzyme suspension were added to prepare a total reaction solution of 565 μl.
상기 제조한 본 발명 백자인 추출물 Ⅰ일정량을 10% 디메틸설폭사이드(DMSO)에 녹여 한 반응당 10㎕로 가하고, 대조군으로는 같은 부피의 용매를, 양성 대조군으로는 리놀렌산(linolenic acid)을 이용하였다.The amount of the white porcelain extract I of the present invention prepared above was dissolved in 10% dimethyl sulfoxide (DMSO) and added to 10 μl per reaction. The same volume of solvent was used as a control and linolenic acid was used as a positive control.
또한, 반응은 상기 준비한 효소 현탁액을 가하여 37℃에서 30분간 진행시킨 후,600㎕의 에틸아세테이트를 가하여 반응을 정지시키고 생성물을 질소 가스를 통해 건조시켰다. 이를 50㎕의 에틸아세테이트로 녹인 후 전량을 실리카 플라스틱 시트 카이젤겔 60 F254(Silica plastic sheet kieselgel 60 F254)상에 점적한 후 전개 용매인 에틸아세테이트:사이클로헥산(cyclohexane)(1:1)을 사용하여 전개하였다.In addition, the reaction was carried out for 30 minutes at 37 ℃ to add the enzyme suspension prepared above, the reaction was stopped by addition of 600 μl of ethyl acetate and the product was dried through nitrogen gas. This is a drip on the total amount of ethyl acetate to the silica plastic sheet kayijel gel 60 F was dissolved in 254 of 50㎕ (Silica plastic sheet kieselgel 60 F 254) and then a developing solvent ethyl acetate: (1: 1) cyclohexane (cyclohexane) Developed using.
실리카 플라스틱 시트를 자연상태에서 건조시킨 후, 동위원소의 양을 측정하기 위해 바스(Bas, 후지필름, 일본) 시스템을 사용하였으며, 건조된 플라스틱 시트와 노출 필름을 함께 바스 카셋트에 넣어 1주일 동안 보관한 후에 필름에 노출된 테스토스테론과 생성된 디하이드로테스토스테론의 동위원소 양을 노출된 강도를 이용해 정량하였다.After drying the silica plastic sheet in the natural state, a bath (Bas, FUJIFILM, Japan) system was used to measure the amount of isotopes, and the dried plastic sheet and the exposed film were put together in a bath cassette and stored for one week. The isotope amounts of testosterone and resulting dihydrotestosterone exposed to the film were then quantified using the exposed intensity.
실험은 2차에 걸쳐 반복적으로 사용하였으며, 그 측정 결과를 바탕으로 각각의 5알파-환원효소 저해율을 하기 계산법으로 산출하였다. 본 발명 백자인 추출물의 5 알파-환원효소 저해 실험 결과를 표 5에 나타내었다.The experiment was used repeatedly for two times, and based on the measurement result, each of 5 alpha-reductase inhibition rates was calculated by the following calculation method. Table 5 shows the results of the 5 alpha-reductase inhibition of the white porcelain extract of the present invention.
이상의 결과에서 살펴본 바와 같이, 본 발명 백자인 추출물 함유제의 경우 5 알파-환원효소 저해 효과가 있음을 알 수 있다.As described in the above results, it can be seen that the extract containing the white porcelain of the present invention has a 5 alpha-reductase inhibitory effect.
시험예 2. 퍼지랫트(Fuzzy rat)를 이용한 5알파-환원효소 저해 효과 시험Experimental Example 2 5-alpha-reductase inhibitory effect test using fuzzy rat
미국의 찰스리버(Charles & River Lab.)에서 판매하는 퍼지랫트(fuzzy rat) 수컷은 자연적으로 성장함에 따라 남성호르몬의 지배를 받아 상기한 바와 같이 테스토스테론이 디하이드로테스토론으로 변환됨에 따라 피지(sebum)가 과다 발생되어 표면이 누렇게 변하는 특징이 있다(Skin Pharmacol. 1997;10(5-6):288-297). 이러한 퍼지렛트를 이용하여 본 발명 백자인 추출물 함유제의 5알파-환원효소 억제효과를 확인하였다.Fuzzy rat males sold by Charles & River Lab, USA, are naturally controlled by male hormones and are sebum as testosterone is converted to dehydrotestosterone as described above. ) And yellowing of the surface due to overproduction ( Skin Pharmacol . 1997; 10 (5-6): 288-297). This purgelet was used to confirm the 5 alpha-reductase inhibitory effect of the white porcelain extract containing the present invention.
남성 호르몬 대사에 관여하는 5알파-환원효소를 저해하는 활성을 지니는 것으로 알려진 피나스테라이드(머크사, 미국) 약물을 퍼지렛드에 투여한 경우, 쥐의 표면이 누렇게 변하지 않았음을 확인하였으며, 백자인을 에틸아세테이트로 추출한 본 발명 백자인 추출물Ⅲ을 프로필렌글리콜:무수에탄올(7:3) 용액에 1.0%의 농도로 희석하여 하루에 두번씩 6주간 도포하여 관찰한 결과, 퍼지랫트의 표면색깔이 변하지 않았음을 확인할 수 있었다(도 5). 따라서, 본 발명 백자인 추출물이 알파-환원효소 저해효과가 있음을 알 수 있다.When Finasteride (Merck, USA), a drug known to have an activity that inhibits 5 alpha-reductase, is involved in testosterone metabolism, it was confirmed that the surface of rats did not turn yellow. The white porcelain extract III of the present invention extracted with acetate was diluted to a concentration of 1.0% in a propylene glycol: anhydrous ethanol (7: 3) solution and applied twice a day for 6 weeks to observe that the surface color of the fuzzy rat did not change. It could be confirmed (Figure 5). Therefore, it can be seen that the white porcelain extract of the present invention has an alpha-reductase inhibitory effect.
시험예 3. 마우스를 통한 백자인 추출물의 모발 생장 효과 시험Test Example 3 Hair Growth Effect Test of White Porcelain Extract through Mouse
상기 제조된 본 발명 백자인 추출물의 건조 엑기스를 2%를 함유하는 30% 함수 에탄올(ethanol) 용액을 제조하여 본 발명 백자인 추출물의 모발 생장 효과를 테스트하였다.30% hydrous ethanol solution containing 2% of the dried extract of the present invention white porcelain extract was prepared to test the hair growth effect of the white porcelain extract of the present invention.
생후 47∼53일된 마우스(C57BL/6)의 등 부위 털을 제거하고, 등 부위 피부가 깨끗한 것을 골라 물질군마다 10마리씩을 선정하여 매일 상기 본 발명 백자인 추출물 시험물질을 개체당 100㎕씩 도포하였다.The hair of the back of 47-53 days old (C57BL / 6) was removed, and the back skin was selected to be clean, and 10 rats were selected for each substance group, and 100 μl of the white porcelain extract test substance was applied daily. .
시간 경과에 따른 모발의 길이 및 모발 생장 정도를 모 제거 후 복원 정도에 따라 점수를 0에서 3까지 부가하여 각각 비교하였다. 모발 생장 정도를 비교하기 위하여, 대조군에는 30% 알코올 용액을 각 개체에 도포하여 모발의 생장 상태를 관찰하였다. 그 결과를 표 6에 나타내었다.The length of hair and the extent of hair growth over time were compared by adding scores from 0 to 3 according to the degree of restoration after hair removal. In order to compare the degree of hair growth, the control group was applied with 30% alcohol solution to each individual to observe the hair growth state. The results are shown in Table 6.
이상의 결과에서, 상기 제조예에 따른 본 발명 백자인 추출물 함유제의 경우 유의적인 모발 생장 촉진 효과가 있음을 확인할 수 있었다.In the above results, it was confirmed that the extract containing agent of the present invention white porcelain according to the preparation example has a significant hair growth promoting effect.
이상의 제조예 및 시험예를 통하여 살펴본 바와 같이, 천연 백자인 생약을 유기용매로 가열 및 분획추출하고 감압농축한 본 발명 백자인 추출물은 5알파-환원효소 저해 효과가 뛰어나고, 제품의 안전성에 영향을 미치지 않는 농도에서 모발 생장을 촉진하는 뛰어난 효과가 있으므로, 이를 첨가하여 화장료를 제조하는 경우, 발모촉진 및 탈모치료용 화장료로 유용하게 이용할 수 있다.As described through the preparation and test examples, the white porcelain extract of the present invention, heated and fractionated with natural white porcelain as an organic solvent and concentrated under reduced pressure, has an excellent 5 alpha-reductase inhibitory effect and does not affect the safety of the product. Since there is an excellent effect of promoting hair growth at a concentration, when added to produce a cosmetic, it can be usefully used as a cosmetic for promoting hair growth and hair loss treatment.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0082716A KR100444102B1 (en) | 2001-12-21 | 2001-12-21 | Cosmetic composition for trichogenousness containing Thujae semen extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0082716A KR100444102B1 (en) | 2001-12-21 | 2001-12-21 | Cosmetic composition for trichogenousness containing Thujae semen extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030052689A KR20030052689A (en) | 2003-06-27 |
KR100444102B1 true KR100444102B1 (en) | 2004-08-11 |
Family
ID=29577441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-0082716A KR100444102B1 (en) | 2001-12-21 | 2001-12-21 | Cosmetic composition for trichogenousness containing Thujae semen extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100444102B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101307304B1 (en) * | 2008-10-01 | 2013-09-11 | (주)아모레퍼시픽 | Composition for treating hair or scalp to prevent hair loss and promote growing hair |
CN117959318B (en) * | 2023-04-14 | 2024-09-24 | 太和康美(北京)中医研究院有限公司 | Platycladus orientalis extract and preparation method and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990007915A (en) * | 1996-02-21 | 1999-01-25 | 히라이카쯔히코 | Coarse and fine polyamide fiber and its manufacturing method |
KR19990079115A (en) * | 1998-04-01 | 1999-11-05 | 박효석 | External solution for hair growth promotion |
KR20010003366A (en) * | 1999-06-23 | 2001-01-15 | 박재준 | Hair growing agent |
KR20010030194A (en) * | 1999-09-03 | 2001-04-16 | 송시훈 | Compositions preventing lose of hair and promoting growth of hair |
KR20020006351A (en) * | 2000-07-12 | 2002-01-19 | 한관석 | Hair protective agents and ins manutacturing method |
KR20020027947A (en) * | 2000-10-06 | 2002-04-15 | 서경배 | Composition capable of inhibiting sebum secretion |
-
2001
- 2001-12-21 KR KR10-2001-0082716A patent/KR100444102B1/en active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990007915A (en) * | 1996-02-21 | 1999-01-25 | 히라이카쯔히코 | Coarse and fine polyamide fiber and its manufacturing method |
KR19990079115A (en) * | 1998-04-01 | 1999-11-05 | 박효석 | External solution for hair growth promotion |
KR20010003366A (en) * | 1999-06-23 | 2001-01-15 | 박재준 | Hair growing agent |
KR20010030194A (en) * | 1999-09-03 | 2001-04-16 | 송시훈 | Compositions preventing lose of hair and promoting growth of hair |
KR20020006351A (en) * | 2000-07-12 | 2002-01-19 | 한관석 | Hair protective agents and ins manutacturing method |
KR20020027947A (en) * | 2000-10-06 | 2002-04-15 | 서경배 | Composition capable of inhibiting sebum secretion |
Also Published As
Publication number | Publication date |
---|---|
KR20030052689A (en) | 2003-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4233734B2 (en) | Skin external preparation for whitening | |
BR0307126B1 (en) | Use of purslane to treat facial wrinkles | |
US20010033849A1 (en) | Cosmetic compositions having retarding action on the regrowth of superfluous hair | |
JPH0517365A (en) | Testosterone 5alpha-reductase inhibitor | |
US20040126351A1 (en) | Topical composition having natural skin anti-irritant ingredient and method of use | |
KR100482694B1 (en) | Liposome base for trichogenousness, Cosmetic composition for trichogenousness containing the same, and Method for improving absorptance of natural ingredients for trichogenousness using the same | |
KR101252550B1 (en) | Cosmetic composition for protecting sebum secretion on the skin | |
JPS63203625A (en) | 5alpha-reductase inhibitor | |
KR20090032583A (en) | Yang yang extract inhibiting the activity of 5α-reductase and sebum secretion inhibiting or acne improving cosmetic composition containing the same | |
KR100444102B1 (en) | Cosmetic composition for trichogenousness containing Thujae semen extract | |
CN101854909B (en) | Skin-whitening agent containing platycodin D | |
JP5000964B2 (en) | Testosterone 5α-reductase activity inhibitor, androgen receptor antagonist, use thereof, and method for suppressing androgen activity expression | |
KR100441726B1 (en) | Cosmetic composition for trichogenousness containing Mantidid ootheca extract | |
BR112012025740B1 (en) | Cosmetic preparation, and use of dihydrodesidrodi-isoeugenol | |
JP2004352659A (en) | External preparation for skin for bleaching | |
JP2010150237A (en) | Ceramide production promotor, and pharmaceutical formulation, external preparation for skin, cosmetic composition and cosmetic product, using the ceramide production promotor | |
KR20020008268A (en) | Testosterone 5 alpha-reductase inhibitors containing extracts of galla rhois | |
JPH11302133A (en) | Cosmetic for scalp and hair | |
KR100406125B1 (en) | A compositions for skin external application containing the torilin | |
KR102093708B1 (en) | A cosmetic composition using Fraxini cortex extract | |
KR101825603B1 (en) | Composition of skin external application for improving alopecia containing Oldenlandia Diffusa Willd extracts | |
JP2001302528A (en) | TESTOSTERONE 5alpha-REDUCTASE INHIBITOR, AGENT FOR HAIR AND SKIN COSMETIC | |
KR101245813B1 (en) | Cosmetic composition comprising lycii fructus extract and uncaria tomentosa extract for whitening of the skin | |
KR20120009915A (en) | Skin external preparation composition for acne and hair loss improvement | |
JP2000169497A (en) | New triterpene and composition including the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20011221 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20031128 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20040726 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20040802 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20040803 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20070528 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20080716 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20090514 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20100707 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20110727 Start annual number: 8 End annual number: 8 |
|
FPAY | Annual fee payment |
Payment date: 20120719 Year of fee payment: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20120719 Start annual number: 9 End annual number: 9 |
|
FPAY | Annual fee payment |
Payment date: 20130718 Year of fee payment: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20130718 Start annual number: 10 End annual number: 10 |
|
FPAY | Annual fee payment |
Payment date: 20140722 Year of fee payment: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20140722 Start annual number: 11 End annual number: 11 |
|
FPAY | Annual fee payment |
Payment date: 20150731 Year of fee payment: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20150731 Start annual number: 12 End annual number: 12 |
|
FPAY | Annual fee payment |
Payment date: 20160624 Year of fee payment: 13 |
|
PR1001 | Payment of annual fee |
Payment date: 20160624 Start annual number: 13 End annual number: 13 |
|
FPAY | Annual fee payment |
Payment date: 20180702 Year of fee payment: 15 |
|
PR1001 | Payment of annual fee |
Payment date: 20180702 Start annual number: 15 End annual number: 15 |
|
FPAY | Annual fee payment |
Payment date: 20190701 Year of fee payment: 16 |
|
PR1001 | Payment of annual fee |
Payment date: 20190701 Start annual number: 16 End annual number: 16 |
|
PR1001 | Payment of annual fee |
Payment date: 20200629 Start annual number: 17 End annual number: 17 |
|
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20220513 |